ABSTRACT The existence of HIV reservoirs in infected individuals under combined antiretroviral therapy (cART) represents a major obstacle toward cure. Viral reservoirs are assessed by quantification of HIV nucleic acids, a method which does not discriminate between infectious and defective viruses, or by viral outgrowth assays, which require large numbers of cells and long-term cultures. Here, we used an ultrasensitive p24 digital assay, which we report to be 1,000-fold more sensitive than classical enzyme-linked immunosorbent assays (ELISAs) in the quantification of HIV-1 Gag p24 production in samples from HIV-infected individuals. Results from ultrasensitive p24 assays were compared to those from conventional viral RNA reverse transcription-quantitative PCR (RT-qPCR)-based assays and from outgrowth assay readout by flow cytometry. Using serial dilutions and flow-based single-cell sorting, we show that viral proteins produced by a single infected cell can be detected by the ultrasensitive p24 assay. This unique sensitivity allowed the early (as soon as day 1 in 43% of cases) and more efficient detection and quantification of p24 in phytohemagglutinin-L (PHA)-stimulated CD4 ϩ T cells from individuals under effective cART. When seven different classes of latency reversal agents (LRA) in resting CD4 ϩ T cells from HIV-infected individuals were tested, the ultrasensitive p24 assay revealed differences in the extent of HIV reactivation. Of note, HIV RNA production was infrequently accompanied by p24 protein production (19%). Among the drugs tested, prostratin showed a superior capacity in inducing viral protein production. In summary, the ultrasensitive p24 assay allows the detection and quantification of p24 produced by single infected CD4 ϩ T cells and provides a unique tool to assess early reactivation of infectious virus from reservoirs in HIV-infected individuals.
reservoirs in HIV-1-infected individuals. We found that viral proteins produced by a single infected cell can be detected by an ultrasensitive p24 assay. This unprecedented resolution showed major advantages in comparison to other techniques currently used to assess viral replication in reactivation studies. In addition, such a highly sensitive assay allows discrimination of drug-induced reactivation of productive HIV based on protein expression. The present study heralds new opportunities to evaluate the HIV reservoir and the efficacy of drugs used to target it.
KEYWORDS CD4 ϩ T cells, HIV cure, HIV reservoir, HIV-1, latency reversal agents, p24, single cell C ombined antiretroviral therapy (cART) efficiently blocks HIV replication but fails to cure infection. This is due to the existence of HIV reservoirs persisting during cART that provide a source of viral rebound upon treatment discontinuation (1, 2) . The persistence of these reservoirs has been associated mainly with the survival and clonal expansion of pools of long-lived infected memory CD4 ϩ T cells and with low-level viral replication in lymphoid tissues where cART has poor penetration (3, 4) . The development of interventions to cure HIV relies on strategies that aim at controlling or eliminating the reservoirs (5) (6) (7) . In this context there is an urgent need for sensitive diagnostic tools to monitor the size and nature of the reservoir. The quantification of cell-associated total or integrated HIV DNA is an easy and sensitive way to estimate the frequency of infected cells, and low levels of HIV DNA at the time of treatment interruption have been associated with delayed viral rebound (8, 9) . However, this technique does not discriminate between the presence of infectious and defective proviruses. Other approaches aim at estimating the inducible reservoir, the potential source of infectious particles that can feed viral replication if treatment is interrupted. These techniques are based on in vitro activation of provirus-carrying cells and the quantification of induced viral products (i.e., HIV RNA or proteins) (10) (11) (12) (13) . The quantification of viral proteins is thought to represent a more accurate readout of efficient viral reactivation. The HIV p24 enzyme-linked immunosorbent assay (ELISA) is the gold-standard laboratory technique to detect the presence of HIV proteins for both diagnosis and pathogenesis studies. However, the picomolar sensitivity of ELISA fails to detect levels of p24 that might be relevant in reservoir reactivation studies, and these studies require expensive and long outgrowth assays that consume large amounts of cells.
The digitization of immunoassay analyte detection using single-molecule array (Simoa) technology represents an important recent advance in ultrasensitive protein detection, achieving detection at femtomolar concentrations (14, 15) . This technique consists of using paramagnetic microbeads coated with a capture antibody that binds the analyte of interest. Similar to an ELISA, the Simoa uses a sandwich formed with a detector antibody. These immunocomplexes are then distributed into 40-femtoliter microwells (each microwell is sized to fit a single bead), and the conversion of the ␤-galactosidase (␤-Gal) substrate (resorufin-␤-D-galactopyranoside [RGP]) into a fluorescent product allows the identification of positive wells (see reference 16 for a schematic representation of the single-molecule array technique). The process is completely automated, leading to accurate quantifications and low technical variation (17) .
Due to the unprecedented sensitivity of this technique, an ultrasensitive p24 assay was previously utilized to precisely diagnose acute HIV infection in plasma samples as accurately as nucleic acid testing (NAT) (18) . In the present study, we aimed to determine the utility of the ultrasensitive p24 assay in reservoir reactivation studies using primary CD4 ϩ T cells infected in vitro and in samples from individuals with low virus reservoirs and levels of viremia.
RESULTS
Detection of HIV p24 at the single-cell level by ultrasensitive p24 assay. We first aimed to determine the range of detection by the HIV ultrasensitive p24 assay in a relevant biological material such as limited amounts of HIV-infected cells. HIV Gag p24 is usually detected at picogram (pg) levels by conventional p24 ELISAs. The ultrasensitive p24 assay standard curve ranged from 0.017 to 37.8 pg/ml, which allowed the quantification of p24 at femtogram (fg) levels (Fig. 1) . This represents an increase in sensitivity of up to 3 logs compared to that of a classical p24 ELISA. We next determined the minimum number of HIV-infected cells needed for p24 detection with the ultrasensitive assay. We infected CD4 ϩ T cells from two HIV-negative controls with infectious HIV-1 NL4-3 in vitro. Productively infected cells, as measured by flow cytometry, were then serially diluted in autologous noninfected CD4 ϩ T cells ( Fig. 2A) . After 24 h, p24 could be detected in supernatants of cultures from both of the HIV-negative controls containing as few as 0.1 HIV-1 infected cells per million total cells. Saturation was observed at approximately 300 HIV-1-positive (HIV-1 ϩ ) cells per million total cells. The detection of viral protein was linear between these values (Fig. 2B) . Detection of p24 produced by 0.1 infected cell is most likely related to infected cells with low levels of protein production that were not detected by flow cytometry and may have caused some underestimation of the number of infected cells initially seeded. Also, as a replicative virus was used in this experiment, some p24 production might have originated from novel infected cells after overnight cell culture. Reevaluation of the frequency of Gag ϩ cells by flow cytometry at the time of ultrasensitive p24 analysis showed, indeed, 2.3 to 6 times more infected cells per well than initially estimated ( Fig.  2B and C) .
Therefore, to exclude this issue, we infected CD4 ϩ T cells with single-cycle HIV NL4-3Δenv/green fluorescent protein (GFP) vesicular stomatitis virus G protein (VSV-G) pseudotyped particles (Fig. 3A) . Two days after infection, we sorted GFP-positive (GFP ϩ ) CD4 ϩ T cells (Fig. 3B ) and analyzed p24 protein expression in cell lysates and supernatants from 1, 10, and 100 GFP ϩ cells after overnight culture in the presence of 20,000 autologous activated feeder CD4 ϩ T cells. The ultrasensitive p24 assay allowed the quantification of intracellular p24 (i.e., in cell lysates) produced by 1 (median and interquartile range [IQR] , 0.26 pg/ml [0.14 to 0.32 pg/ml]), 10 (2.38 pg/ml [1.74 to 3.39 pg/ml]), and 100 (26.22 pg/ml [22. 43 to 38.91 pg/ml]) HIV-infected CD4 ϩ T cells (Fig. 3C) . The levels of p24 released in the culture supernatants by the infected cells were comparable to those observed for the corresponding cell lysates: 1 cell (0.29 pg/ml; IQR of 0.15 to 0.41 pg/ml), 10 cells (1.54 pg/ml; IQR of 0.83 to 2.65 pg/ml), and 100 cells (25.74 pg/ml; IQR of 20.48 to 28.58 pg/ml). Consistently, amounts of intracellular and released p24 were strongly correlated (r ϭ 0.9698; P Ͻ 0.0001) (Fig. 3D) . p24 protein concentrations produced by single infected cells ranged from 0.096 to 0.36 pg/ml, which corresponded to values at least 5 times higher than the limit of quantification (LOQ) and were much higher than the background signal obtained with noninfected CD4 ϩ T cells, which were below the LOQ of the technique (0.004 pg/ml; IQR of 0.002 to 0.007). To ensure confidence in further analyses, a conservative limit of quantification of 0.017 pg/ml, corresponding to the lower value of the p24 standard reference, was used. Importantly, p24 values obtained from 1 and 10 infected cells were lower than the LOQs of conventional p24 ELISAs (Fig. 1 ) and could be quantified only by the ultrasensitive p24 assay.
HIV p24 levels correlate with the production of HIV RNA. We compared the levels of p24 protein produced by HIV-infected cells measured with the ultrasensitive assay with the detection of HIV-1 RNA by PCR, which is considered one of the most sensitive markers of viral reactivation. We sorted 1, 10, and 100 GFP ϩ infected cells and quantified p24 and viral RNA in the supernatant after overnight culture. In 3 out of 10 single, sorted GFP ϩ cells, neither p24 nor viral RNA could be detected, suggesting a technical problem during sorting. All supernatants positive for HIV RNA were also positive for HIV p24, and a strong correlation (r ϭ 0.9014; P Ͻ 0.0001) (Fig. 3E ) between levels of p24 and RNA was observed. These results reinforce the high sensitivity of the p24 ultrasensitive digital immunoassay.
HIV p24 levels in single infected cells correlate with the FI of GFP. We next analyzed if the ultrasensitive assay allowed detection of differences in the quantities of p24 production per infected cell. We observed some variability of p24 levels from single HIV-infected cells (Fig. 3E) . We hypothesized that this variability was due to different Relationship between the amount of intracellular p24 and released p24 present in supernatant after culture overnight. Blue, orange, and black symbols represent 1, 10, and 100 infected cells, respectively. (E) Relationship between the amount of p24 and RNA in culture supernatant. Blue, orange, and black symbols represent 1, 10, and 100 infected cells, respectively. Three samples were below the limit of quantification with both techniques and are represented by gray circles. Arbitrary values were assigned to represent these negative points. (F) Relationship between the amount of intracellular p24 and GFP expression recorded during single-cell index sorting (DIVA; BD Bioscience). Two samples that were below the limit of quantification with the ultrasensitive p24 assay are represented by gray circles. All correlations were calculated using a nonparametric Spearman test. levels of protein production by individual cells rather than to technical variability. To elucidate this point, we sorted single HIV-infected GFP ϩ CD4 ϩ T cells and evaluated the range of GFP fluorescence intensities (FIs) per cell. Thirty-nine cells were sorted and processed, and we could detect p24 production for all of them. Intracellular p24 levels and GFP FI for each cell were significantly correlated (r ϭ 0.7215; P Ͻ 0.0001) (Fig. 3F) . Therefore, the ultrasensitive assay can detect p24 produced by one single infected cell, and the variability in intracellular p24 levels reflects different viral protein production levels of individual infected cells.
Monitoring virus reactivation from total CD4 ؉ T cells by ultrasensitive p24 assay. We next assessed the ability of the ultrasensitive p24 assay to detect HIV-1 reservoir reactivation from CD4 ϩ T cells isolated from peripheral blood of cART-treated individuals with undetectable viremia. We first used supernatants of phytohemagglutinin-L (PHA)-activated CD4 ϩ T cell cultures from six HIV-infected subjects in which HIV-1 Gag p24 was detectable by flow cytometry (Fig. 4A and B) (median time of HIV-1 detection after reactivation, 14 days). Using the ultrasensitive assay, HIV-1 p24 was detectable between days 1 and 7 (median, 3.5 days) for all individuals and reached saturation between days 5 and 10 (Fig. 4B) . Crucially, a positive result from ultrasensitive p24 assay preceded the detection of Gag ϩ cells by flow cytometry by 7 to 10 days.
We then extended our analyses to supernatants of CD4 ϩ T cells from an additional 29 randomly selected HIV-infected individuals with suppressed viremia under cART for (19) . HIV production measured by ultrasensitive p24 assay was detectable in cultures from 23 out of 29 individuals at day 7 (Fig. 4C) . Importantly, p24 was detectable as early as day 1 postactivation in cultures from 43% of the individuals (Fig. 4C) . Of note, HIV p24 levels, as determined by the ultrasensitive immunoassay, increased over time in cultures, irrespective of whether p24 could be detected by flow cytometry. These results demonstrate an unprecedented ability of the ultrasensitive p24 assay to reveal HIV-1 spreading from the CD4 ϩ T cell reservoir.
Monitoring the efficiency of LRA by ultrasensitive p24 quantification assay. Since the ultrasensitive p24 assay provides a unique tool to detect viral protein production at low levels, we investigated if such a high sensitivity might provide new insights about the differential capacity of distinct latency-reversing agents (LRA) to induce viral reactivation. In a previous study (20) , we evaluated viral reactivation from resting CD4 ϩ T cells from individuals with undetectable viremia at different time points (Fig. 5A) (20) . Here, we tested p24 levels in supernatants (n ϭ 144), known to be HIV RNA positive from our previous study (20) , from stimulated resting CD4 ϩ T cells from 10 individuals for whom material was still available. We detected p24 in 18.75% (27/144) of supernatants (median, 0.90 pg/ml; IQR of 0.13 to 1.87 pg/ml). Gag p24 could be detected in only 1 of 65 supernatants with HIV RNA levels of Ͻ2,000 copies, suggesting that these weak levels of HIV RNA could correspond to abortive viral reactivations. Similarly to results from our in vitro infection experiments (Fig. 3E) , a significant correlation between the ultrasensitive p24 assay and HIV RNA levels was observed in p24-positive cultures (r ϭ 0.53; P ϭ 0.005) (Fig. 5B,  orange dots) . However, the correlation coefficient was weaker when p24-negative samples (Fig. 5B , blue dots) were taken into consideration (r ϭ 0.39; P ϭ 0.0004). RNA levels were overall lower in p24-negative cultures (median HIV RNA copies/ml [IQR] in p24-negative and positive cultures, respectively, of 5,260 copies/ml [3,385 to 13,025 copies/ml] and 19,425 copies/ml [4,249 to 94,313 copies/ml]; P ϭ 0.004). Nevertheless, the HIV RNA range in p24-negative samples was similar to the one in positive samples ( Fig. 5B and C) and well within the RNA levels for which we could detect p24 in in vitro experiments (Fig. 3E ). This suggests that the absence of detectable p24 in many HIV-1 RNA-positive cultures could not be solely related to insufficient sensitivity of the p24 assay. It is likely that p24-positive samples identified the reactivation of replicationcompetent viruses that multiplied in culture, reaching higher levels of HIV RNA.
In agreement with our previous analysis (20) , no significant differences were found in the levels of HIV RNA in the supernatants treated with different LRA and the controls tested here (P ϭ 0.12) (Fig. 5C ). Of note, very high levels of HIV RNA were even detected in some cultures in the absence of stimulation (Fig. 5A) . In contrast, a significant difference (P ϭ 0.03) was observed in the frequency of p24-positive samples between the differentially stimulated cell cultures (Fig. 5C ). In particular, p24 production was not detected in supernatants from nonstimulated cultures or after stimulation with chaetocin. The frequency of p24-positive cultures treated with prostratin (35.3%) and the positive-control allogeneic stimulation (33.3%) or anti-CD2/anti-CD28 (35.3%) tended to be significantly different from that of mock cultures in post hoc analyses (P values of 0.065, 0.078, and 0.073, respectively). The quantification of p24 by ultrasensitive digital immunoassay revealed that certain latency-reversing agents were more proficient at inducing production of viral proteins in resting CD4 ϩ T cells from HIV-infected individuals.
DISCUSSION
Interpreting the efficacy of HIV curative strategies relies on how HIV reservoirs and reactivation are measured (21, 22) . To date, the reservoir is mostly quantified by PCR-based techniques, notably as total/integrated HIV DNA or cell-associated RNA, or by a viral outgrowth assay (VOA) (23, 24) . The quantification of viral DNA may overestimate the HIV reservoir since it quantifies both productive and defective proviruses. In contrast, the VOA may underestimate the reservoir up to 60-fold (11, 25) since it seems capable of only partial detection of the viral progeny able to spread to neighboring cells due to the stochastic nature of viral induction (21) . In addition, the VOA requires large amounts of cells and over 2 weeks of cell culture. More recently, the Tat/Revinduced limiting-dilution assay (TILDA) was developed to complement the other tests (12) . It works in a VOA-based system and quantifies multiply spliced HIV RNAs, which are early viral transcripts produced after cell activation. The size of the inducible reservoir estimated by TILDA is smaller than the total HIV DNA but larger than replication-competent virus measured by VOA. Despite the advantages of the TILDA in comparison to the VOA in terms of cost, blood volume, and experimental time required, the TILDA does not directly measure the production of viral antigens or replicative virus production. We show here that an ultrasensitive ELISA also allows the detection and quantification of p24 produced by a single HIV-1-infected-CD4 ϩ T cell. The ultrasensitive p24 assay could greatly improve the readout of both the VOA and TILDA, notably 
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Journal of Virology by reducing the time between virus reactivation from the translation-competent reservoir and detection of p24 and by elucidating whether cells with inducible multiply spliced transcripts as measured by the TILDA produce viral antigens. It is important to mention that the cost of the ultrasensitive p24 assay is fairly similar to that of conventional p24 ELISA kits. We demonstrated the applicability of the ultrasensitive p24 assay in HIV reactivation studies in samples from individuals with low virus reservoirs or levels of viremia. The ultrasensitive p24 assay displayed notable advantages compared with other techniques. In comparison to classical Gag p24 flow cytometry, the ultrasensitive p24 assay preceded by around 11 days the detection of positive cultures and strongly increased the frequency of detectable HIV reactivation. In comparison to RNA quantification in culture supernatants, we show that the ultrasensitive p24 assay may discriminate between effective LRA and drugs that might initiate transcription but fail to trigger detectable p24 production. When p24 was detected after culture of resting CD4 ϩ T cells from HIV-infected individuals under different conditions, the levels of p24 produced by infected cells were strongly correlated with the levels of HIV-1 RNA, in line with the results that we obtained in the infection in vitro experiments. However, production of HIV-1 RNA was not always accompanied by production of p24. This was not due to a difference in the sensitivities of the two techniques. Moreover, discrepancies were observed between samples producing similar levels of HIV RNA. Our results suggest, rather, that the concurrent production of HIV RNA and p24 may depend on the quality of the stimulation provided by LRA. It has been suggested that some LRA, such as some histone deacetylase (HDAC) inhibitors, are able to induce only HIV-1 transcription but not complete viral reactivation (26) (27) (28) . Our results are in agreement with these reports. Among the drugs tested, prostratin displayed the best capacity to induce viral antigen production. This is in line with the recent work of Jones and colleagues describing prostratin as a good inducer of viral antigens stimulating CD8 ϩ T cell responses (29) . Because our experiments were conducted in the absence of antiretroviral drugs, we cannot formally exclude the possibility that prostratin, compared to the other LRA analyzed, may have favored activation of bystander CD4 ϩ T cells and enabled viral spread. However, it is important that we used resting CD4 ϩ T cells, and prostratin does not induce T cell activation or allow HIV-1 infection of CD4 ϩ T cells in the absence of other stimuli (30) .
Our data strongly support that HIV RNA quantification and the ultrasensitive Gag p24 assay are complementary markers to be analyzed in the evaluation of efficient viral reactivation strategies.
Overall, the ultrasensitive p24 assay provides a unique tool to measure viral production at the single-cell level and to monitor the translation-competent reservoir in HIV-infected individuals. While it is likely that not all cells harboring a translationcompetent provirus are able to produce infectious HIV-1 (11), the release of viral antigens may contribute to the recognition of the cell by the immune system and also to persistent immune activation and HIV-1 pathogenesis. Therefore, these antigenproducing cells should be preferential targets for HIV cure strategies.
MATERIALS AND METHODS
Ethics statement. Blood samples from HIV-negative controls were obtained from the French Blood Bank (Etablissement Français du Sang) in the context of a collaboration agreement with the Institut Pasteur (C CPSL UNT, number 15/EFS/023). Fifty-milliliter blood samples were obtained from HIV-1 controllers (HIC; ANRS CO21 Codex cohort) and HIV-1-infected individuals under successful cART who were followed at the Kremlin-Bicêtre University Hospital (France). All participants provided written consent to participate in the study, which was approved by the regional investigational review board (Comité de Protection des Personnes Ile-de-France VII, Paris, France) and performed according to European guidelines and the Declaration of Helsinki.
Purification and infection in vitro of CD4 ؉ T cells. Peripheral blood mononuclear cells (PBMCs) from HIV-negative controls were isolated by gradient separation using LSM 1077 lymphocyte separation medium and Sepmate tubes (Stemcell Technologies). CD4 ϩ T cells were purified by positive selection using anti-CD4 antibody-coupled magnetic beads (catalog number 18052, EasySep Human CD4 Positive Selection kit; Stemcell Technologies). Purified CD4 ϩ T cells were activated for 3 days with phytohemagglutinin-L (PHA-L; 1 g/ml) and IL-2 (100 U/ml). Activated CD4 ϩ T cells were infected with productive HIV-1 NL4-3 or single-round NL4-3ΔenvΔNef/GFP HIV-1 particles pseudotyped with VSV-G for 1 h with spinoculation (1,200 ϫ g at room temperature), followed by 1 h of incubation at 37°C. Cells were then washed with R10 medium (RPMI, Glutamax, 10% fetal calf serum, and penicillin-streptomycin) containing IL-2 and incubated at 37°C for 48 h.
Flow-based sorting of GFP ؉ CD4 T cells. GFP ϩ CD4 ϩ T cells (1, 10, 100, 1,000 and 10,000) were sorted a minimum of 10 times each in 96-well plate using a FACSAria III cell sorter (BD Biosciences). Cells were either lysed immediately after sorting or were kept overnight in culture with 20,000 activated CD4 ϩ T cells from the same HIV-negative control as the feeder layer. Cells were lysed with NP-40 buffer (1% NP-40, 0.1% SDS, 150 mM NaCl, 50 mM Tris-HCl, protease inhibitor cocktail), and supernatants were inactivated by the addition of Triton X-100 to 2% and incubation of the sample for 30 min at room temperature. Supernatants and cell lysates were stored at Ϫ80°C prior to analysis. Quantification of p24 by Simoa was performed in both cell lysates and culture supernatants.
HIV-1 reactivation from bulk CD4 ؉ T cells from HIV-1-positive individuals. PBMCs from individuals under successful cART (Table 1) were isolated by Ficoll gradient purification, and CD4 ϩ T cells were purified using anti-human CD4 magnetic beads, according to the manufacturer's protocol (Miltenyi Biotec). CD4 ϩ T cells were stimulated with PHA and IL-2 in a 12-well plate at a concentration of 1 to 7 million cells/ml in 3 ml. After 24 h, cells were washed to remove PHA and resuspended in medium containing IL-2. Every 1 to 2 days, 1 ml of supernatant was harvested and replaced with fresh medium. At the same time points (see Fig. 4 ), cells were evaluated for p24 expression by flow cytometry.
HIV-1 reactivation by latency-reversing agents from resting CD4 ؉ T cells of HIV-1-infected individuals. An LRA HIV reactivation assay was performed in samples from HIC and cART individuals from Kremlin-Bicêtre University Hospital (France). The characteristics of the patients enrolled in this study and the detailed protocol used for the reactivation assay are described in Noel et al. (20) . Briefly, quiescent CD4 ϩ CD25 Ϫ CD69 Ϫ HLA-DR Ϫ T cells were purified by negative selection. For viral reactivation, 500,000 quiescent CD4 ϩ T cells/well were cultured in 48-well plates in the presence of prostratin (2.5 M), chaetocin (90 nM), SAHA (2.5 M), 5-AzadC (1 M), HMBA (5 mM), or IL-7 (10 ng/ml). Anti-CD2 plus anti-CD28 antibodies at saturating concentrations, PHA (0.25 mg/ml) plus IL-2 (25 ng/ml), and PHA preactivated allogeneic CD8-depleted T cells from HIV-negative controls were used as positive controls. Importantly, no activated CD4 ϩ T cells were added to these cultures, and the results reflect the capacity of these LRA to induce viral production rather than the capacity of these drugs to activate bystander cells that will support efficient HIV replication. Supernatants (200 l) were collected at days 1, 3, 6, and 14. The cultures were replenished with fresh medium alone on day 1 and with medium plus reactivating agents at days 3 and 6. Supernatants were stored at Ϫ80°C before analyses.
p24 ultrasensitive digital immunoassay (Simoa). HIV capsid p24 protein was quantified by an ultrasensitive p24 assay (Simoa; Quanterix) according to the manufacturer's instructions. A quantification range of 0.017 to 37 pg/ml was utilized in the present study. For the in vitro assays, at least 10 biological replicates were performed for each condition (cell lysates and culture supernatants). For the reactivation assay, each sample was tested once due to limited volume availability. Four-parameter logistic (4PL) regression fitting was used to estimate the concentration of p24. For correlation analyses, wells testing negative for p24 were assigned a value of 0.008 pg/ml. Intracellular p24 staining. Cells were fixed with phosphate-buffered saline (PBS) containing 4% paraformaldehyde for 10 min. Cells were then washed with PBS and stained using anti-Gag antibody (clone KC57-FITC; Beckman Coulter) diluted (1:500) in PBS containing 1% bovine serum albumin (BSA) and 0.05% saponin. After 15 min, cells were washed, resuspended in PBS, and analyzed using a FACSCanto II flow cytometer (BD Biosciences). Analyses were done on FlowJo, version 9.3.2, software (FlowJo, LLC).
HIV-1 RNA quantification. Viral RNA was extracted from 100 l of culture supernatant using a NucleoSpin 8 Virus Core kit (Macherey-Nagel), according to the manufacturer's instructions. HIV-1 RNA levels in culture supernatants were obtained using the a Generic HIV Charge Virale kit (Biocentric) according to the manufacturer's instructions. Detection range was from 300 to 5 ϫ 10 6 copies/ml. The measuring range of the assay was determined to be linear from 165 to 5 ϫ 10 6 copies/ml.
Statistical analyses. Statistical analyses were performed using GraphPad Prism, version 6.05, and SigmaPlot (Systat Software). Correlations were performed using the Spearman test. Analysis of variance (ANOVA) and the Holm-Sidak post hoc method were used for multigroup analyses. Differences were considered significant at a P value of Ͻ0.05.
ACKNOWLEDGMENTS
This work was supported by grants from MSDAVENIR (http://www.msdavenir.fr/fr/ accueil/) and ANRS-France Recherche Nord & Sud Sida-HIV Hépatites (http://anrs.fr/) to A.S. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
We thank the Center for Human Immunology (CIH) at Institut Pasteur for technical
